16 results on '"A. Timillero"'
Search Results
2. Prevalence and Risk Factors for Nosocomial Infections in Hospitals of the Veneto Region, North-Eastern Italy
- Author
-
Pellizzer, G., Mantoan, P., Timillero, L., Allegranzi, B., Fedeli, U., Schievano, E., Benedetti, P., Saia, M., Sax, H., and Spolaore, P.
- Published
- 2008
- Full Text
- View/download PDF
3. A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
- Author
-
Rocca, Bianca, Tosetto, Alberto, Betti, Silvia, Soldati, Denise, Petrucci, Giovanna, Rossi, Elena, Timillero, Andrea, Cavalca, Viviana, Porro, Benedetta, Iurlo, Alessandra, Cattaneo, Daniele, Bucelli, Cristina, Dragani, Alfredo, Di Ianni, Mauro, Ranalli, Paola, Palandri, Francesca, Vianelli, Nicola, Beggiato, Eloise, Lanzarone, Giuseppe, Ruggeri, Marco, Carli, Giuseppe, Elli, Elena Maria, Carpenedo, Monica, Bertozzi, Irene, Paoli, Chiara, Randi, Maria L, Ricco, Alessandra, Specchia, Giorgina, Vannucchi, Alessandro Maria, Rodeghiero, Francesco, Patrono, Carlo, and De Stefano, Valerio
- Subjects
Settore MED/15 - MALATTIE DEL SANGUE ,essential thrombocythemia ,Settore BIO/14 - FARMACOLOGIA - Published
- 2020
4. Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.
- Author
-
Tosetto, Alberto, Rocca, Bianca, Petrucci, Giovanna, Betti, Silvia, Soldati, Denise, Rossi, Elena, Timillero, Andrea, Cavalca, Viviana, Porro, Benedetta, Iurlo, Alessandra, Cattaneo, Daniele, Bucelli, Cristina, Dragani, Alfredo, Di Ianni, Mauro, Ranalli, Paola, Palandri, Francesca, Vianelli, Nicola, Beggiato, Eloise, Lanzarone, Giuseppe, and Ruggeri, Marco
- Subjects
ASPIRIN ,BLOOD platelets ,THROMBOCYTOSIS ,MYELOPROLIFERATIVE neoplasms ,GENE frequency ,BLOOD platelet aggregation ,PLATELET count ,OLDER patients - Abstract
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by enhanced platelet production and thrombotic complications. The inhibition of platelet cyclooxygenase (COX) activity by the standard once‐daily aspirin is mostly incomplete due to accelerated thrombopoiesis. The phase II Aspirin Regimens in EsSential thrombocythemia (ARES) trial has recently compared the efficacy of once‐ vs. twice‐ or three‐times daily low‐dose aspirin in inhibiting platelet thromboxane (TX) A2 production, as reflected by serum (s) TXB2 measurements. The present substudy characterized the determinants of the highly variable response to the standard aspirin 100 mg once‐daily regimen in fully compliant patients with ET and the effects of the experimental dosing regimens on response variability. By multivariable analysis, the platelet count (directly) and cytoreductive treatment (inversely) were significantly associated with sTXB2 values in 218 patients with ET. However, the platelet count positively correlated with sTXB2 in patients not being treated with cytoreductive drugs (ρ = 0.51, P < 0.01, n = 84), but not in patients on cytoreduction. Patients in the lowest sTXB2 quartile were older, more often on cytoreductive drugs, had lower platelet count and Janus‐Associated Kinase2 (JAK2)‐V617F allele frequency as compared with patients in the upper sTXB2 quartiles. After 2 weeks of a twice‐ or 3‐times daily aspirin regimen, the association between the platelet count and sTXB2 became similar in cytoreduced and non‐cytoreduced patients. In conclusion, the platelet count appears the strongest determinant of TXA2 inhibition by once‐daily low‐dose aspirin in ET, with different patterns depending of cytoreductive treatment. More frequent aspirin dosing restores adequate platelet inhibition and reduces interindividual variability, independently of cytoreduction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Linkage of microbiology reports and hospital discharge diagnoses for surveillance of surgical site infections
- Author
-
Spolaore, P., Pellizzer, G., Fedeli, U., Schievano, E., Mantoan, P., Timillero, L., and Saia, M.
- Published
- 2005
- Full Text
- View/download PDF
6. Prevalence and risk factors for nosocomial infections in 19 hospitals of Veneto Region (Italy)
- Author
-
Pellizzer, G., Timillero, L., Mantoan, P., Allegranzi, B., Saia, M., Benedetti, P., Pegoraro, E., and Spolaore, P.
- Published
- 2004
7. A computerised system of administrative data for nosocomial infection monitoring
- Author
-
Saia, M., Timillero, L., Mantoan, P., Allegranzi, B., Pellizzer, G., and Spolaore, P.
- Published
- 2004
8. Regional and systemic prophylaxis with teicoplanin in total knee arthroplasty A tissue penetration study
- Author
-
Lazzarini, Luca, Novelli, Andrea, Marzano, Nicola, Timillero, Lia, Fallani, Stefania, Viola, Renato, and de Lalla, Fausto
- Published
- 2003
- Full Text
- View/download PDF
9. Risk factors for lipodystrophy in the CISAI cohort
- Author
-
Bonfanti, Paolo, Gulisano, Cecilia, Ricci, Elena, Timillero, Lia, Valsecchi, Laura, Carradori, Silvia, Pusterla, Luigi, Fortuna, Paolo, Miccolis, Sebastiano, Magnani, Carlo, Gabbuti, Andrea, Parazzini, Fabio, Martinelli, Canio, Faggion, Ivano, Landonio, Simona, Quirino, Tiziana, and Vigevani, GianMarco
- Published
- 2003
- Full Text
- View/download PDF
10. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
- Author
-
Irene Bertozzi, Elena Maria Elli, Giuseppe Lanzarone, Bianca Rocca, Daniele Cattaneo, Viviana Cavalca, Chiara Paoli, Alessandro Rambaldi, Linda Turnu, Silvia Betti, Alessandra Ricco, Denise Soldati, Andrea Timillero, Nicola Vianelli, Carlo Patrono, Monica Carpenedo, Giorgina Specchia, Francesca Palandri, Giovanna Petrucci, Marco Ruggeri, Laura Lissandrini, Francesco Rodeghiero, Elena Rossi, Alfredo Dragani, Alberto Tosetto, Alessandra Iurlo, Alessandro M. Vannucchi, Guido Finazzi, Maria Luigia Randi, Paola Ranalli, Giuseppe Carli, Eloise Beggiato, and Valerio De Stefano
- Subjects
Oncology ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,lcsh:RC254-282 ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Polycythemia vera ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Dosing ,Essential Thrombocythemia ,Aspirin ,biology ,business.industry ,Hematology ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Clinical trial ,Regimen ,Settore MED/15 - MALATTIE DEL SANGUE ,Pharmacodynamics ,biology.protein ,Cyclooxygenase ,business ,030215 immunology ,medicine.drug - Abstract
Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.
- Published
- 2018
11. Predictors of protease inhibitor-associated adverse events
- Author
-
Bonfanti, P., Ricci, E., Landonio, S., Valsecchi, L., Timillero, L., Faggion, I., and Quirino, T.
- Published
- 2001
- Full Text
- View/download PDF
12. RUVIVAL Publication Series Volume 1
- Author
-
Hügel, Stefan, Timillero, Giovanni, Schaldach, Ruth, Otterpohl, Ralf, Vrbavac, Isidora, and Carmesin, Tina
- Subjects
literature review ,sustainable rural development ,Terrassenbau ,erosion control ,Ingenieurwissenschaften [620] ,nachhaltige ländliche Entwicklung ,Agroforstwirtschaft ,agroforestry ,check dams ,Erosionsschutz ,ddc:620 ,living terraces ,Geröllsprerre - Abstract
The RUVIVAL Publication Series is part of the open source learning project RUVIVAL. All topics of RUVIVAL Volume 1 are related on several levels and are part of restoration engineering. Each contribution in this publication is connected to further interactive multimedia material, which can be reached under http://www.hoou.de. The literature review papers are a collaboration of Master students, PhD students and researchers at the Institute of Wastewater Management and Water Protection (AWW) at Hamburg University of Technology. This volume consists of 3 literature review papers. The first reviews agroforestry, the practice of including trees or other woody perennial plants into agricultural systems, including crop and livestock production. It explains the challenges and benefits of this practice and provides an example of its implementation within the Slope Farming Project in Arba Minch, Ethiopia. The second paper introduces the concept of living terraces, which constitute a combination of erosion control measures on slopes. They are similar to contour hedgerows, but are constructed with the aim of accumulating soil on the uphill side of the tree row, so that in the long run, bench terraces are formed on their own. Their role as part of rainwater harvesting practices is explained in more depth in the paper. Finally, the third literature review provides insight into check dams, structures built across channels to reduce erosion by lowering water speed and accumulating sediments during floods. Check dams are often introduced in degraded areas and they represent one of the most used stabilisation measures worldwide, because of their relative simplicity and easy implementation. This paper also introduces a well-known case study in the Loess Plateau, China. Die RUVIVAL-Publikationsreihe ist Teil des Open-Source-Lernprojekts RUVIVAL. Alle Themen von RUVIVAL Volume 1 stehen auf mehreren Ebenen miteinander in Beziehung und sind Teil des Restaurierungsingenieurwesens. Jeder Beitrag in dieser Publikation ist mit weiteren interaktiven Lerninhalten verbunden, die unter http://www.hoou.de eingesehen werden können. Die Literaturübersichten sind eine Zusammenarbeit von Masterstudent*innen, Doktorand*innen und Forschenden des Instituts für Abwasserwirtschaft und Gewässerschutz (AWW) der Technischen Universität Hamburg. Diese Ausgabe besteht aus 3 Literaturübersichten. Die erste befasst sich mit der Agroforstwirtschaft, der Praxis der Einbeziehung von Baumarten oder anderen mehrjährigen Holzpflanzen in landwirtschaftliche Systeme, einschließlich der Nutzpflanzen- und Tierproduktion. Erläutert werden die Herausforderungen und Vorteile dieser Praxis, ergänzt durch ein Beispiel für ihre Umsetzung im Rahmen des Slope Farming Project in Arba Minch, Äthiopien. Der zweite Beitrag stellt das Konzept der lebenden Terrassen vor, die eine Kombination von Erosionsschutzmaßnahmen an Hängen darstellen. Sie ähneln den Kontur-Hecken, werden aber mit dem Ziel konstruiert, an der Hangseite der Gehölzreihen Boden anzustauen, so dass sich auf lange Sicht selbständig Terassenbänke bilden. Ihre Rolle als Teil der Regenwassernutzung wird in der Publikation näher erläutert. Schließlich gibt die dritte Literaturübersicht Einblicke in die Thematik der Geröllsprerren, die über Wasserläufe gebaut werden, um die Erosion durch Senkung der Wassergeschwindigkeit und Anhäufung von Sedimenten bei Überschwemmungen zu verringern. Geröllsprerren werden häufig in von Erosion beeinträchtigten Gegenden angewandt und stellen aufgrund ihrer relativen Einfachheit und leichten Umsetzbarkeit eine der weltweit am häufigsten verwendeten Stabilisierungsmaßnahmen dar. Des weiteren stellt diese Publikation auch eine Fallstudie im Löss-Plateau in China vor.
- Published
- 2017
13. Predictors of protease inhibitor-associated adverse events
- Author
-
Simona Landonio, Elena Ricci, Tiziana Quirino, Ivano Faggion, Timillero L, Paolo Bonfanti, Laura Valsecchi, Bonfanti, P, Ricci, E, Landonio, S, Valsecchi, L, Timillero, L, Faggion, I, and Quirino, T
- Subjects
Adult ,Male ,Safety Management ,medicine.medical_specialty ,Efavirenz ,HIV Infections ,Lower risk ,Cohort Studies ,chemistry.chemical_compound ,Risk Factors ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Humans ,Protease Inhibitors ,Prospective Studies ,Risk factor ,Adverse effect ,Pharmacology ,Surveillance ,business.industry ,Stavudine ,Lamivudine ,General Medicine ,Adverse reaction ,chemistry ,Protease inhibitor ,Immunology ,HIV-1 ,Regression Analysis ,Female ,Ritonavir ,business ,Saquinavir ,medicine.drug - Abstract
Risk factors in the development of adverse reactions in HIV-1-infected patients treated with highly active antiretroviral therapy (HAART) containing protease inhibitors are poorly understood. To identify predictors of protease inhibitor-associated adverse events, we are conducting a prospective, cohort, multicenter study on HIV-positive patients starting treatment with at least one protease inhibitor. Rate ratios (RR) of adverse events were calculated, and logistic regression was used to adjust simultaneously for the potentially confounding effects of selected variables, according to the Cox model. A total of 1477 patients have been enrolled up to April 2000, having an average age of 37.1 years (SD ± 8.1); 1066 (72.2%) were male. Where risk factors for HIV infection are concerned, the distribution was as follows: 48.1% intravenous drug users, 31.6% heterosexual contacts, 16.2% homosexual males and 0.7% blood transfusion. Average CD4+ lymphocyte count at enrollment was 265 cells/mmc (SD ± 201). Average follow-up time is equal to 17.8 months (range 1–32). The risk of developing adverse reactions is significantly increased in female patients, older patients, hemophiliac subjects and in subjects with hepatitis. Patients treated with ritonavir, the association ritonavir-saquinavir HGC, stavudine and efavirenz have significantly increased incidence of adverse reactions in PI-containing regimens; conversely, saquinavir HGC, zidovudine and lamivudine use was associated with a lower risk of developing adverse reactions.
- Published
- 2001
14. Prevalence and risk factors for nosocomial infections in hospitals of the Veneto region, north-eastern Italy
- Author
-
Ugo Fedeli, P. Mantoan, G. Pellizzer, Benedetta Allegranzi, P. Benedetti, Hugo Sax, L. Timillero, Elena Schievano, Paolo Spolaore, and Mario Saia
- Subjects
Microbiology (medical) ,Adult ,Italy/epidemiology ,Male ,medicine.medical_specialty ,Pediatrics ,Staphylococcus aureus ,Multivariate analysis ,Adolescent ,medicine.medical_treatment ,Urinary system ,Enterococcus/isolation & purification ,Charlson index ,Cross Infection/epidemiology/microbiology ,Severity of Illness Index ,Pseudomonas aeruginosa/isolation & purification ,Risk Factors ,Intensive care ,Severity of illness ,Prevalence ,Medicine ,Intubation ,Humans ,ddc:610 ,Child ,Aged ,Aged, 80 and over ,Cross Infection ,Analysis of Variance ,business.industry ,Infant ,General Medicine ,Middle Aged ,Anti-Bacterial Agents ,Long-term care ,Anti-Bacterial Agents/therapeutic use ,Infectious Diseases ,Italy ,Staphylococcus aureus/isolation & purification ,Child, Preschool ,Emergency medicine ,Pseudomonas aeruginosa ,Female ,business ,Hospital Units ,Central venous catheter ,Enterococcus - Abstract
OBJECTIVE: The study aimed to assess prevalence and risk factors for nosocomial infection (NI) in 21 hospitals of the Veneto Region (Italy). METHODS: In May 2003, a one-week-period prevalence study of NI was carried out in 21 hospitals, representing 63% of all hospital beds for acute patients of the Veneto Region. Intensive care units represented 84% of all intensive care beds of the Region. Long term care, neonatal intensive care, burn, psychiatric and dermatology units were excluded. RESULTS: Overall, 6,352 patients were surveyed. The prevalence of NI was 7.6% (range 2.6%-17.7%), while 6.9% of patients (range 2.6%-15.5%) were affected by at least one NI. The prevalence of patients with NI in medical, surgical and intensive care areas was 6.6%, 5.0% and 25.8%, respectively. The sites most frequently affected were the following: urinary tract (28.4%), surgical site (20.3%), blood stream (19.3%), pulmonary and lower respiratory tract (17.6%). At multivariate analysis risk factors independently associated to NI were: Charlson index score >1, severity of underlying disease, exposure to antibiotics, surgical intervention, trauma at admission, presence of central venous catheter >24 h, urinary catheter, intubation, tracheostomy, and duration since admission >15 days. CONCLUSION: The study provided baseline data of NI in the Veneto Region hospitals. It showed that NI are frequent, and display a wide inter-hospital variability of rates. The highest prevalence has been reported in intensive care units. The unusual high frequency of blood stream infections and the relatively lower prevalence rate of surgical site infections highlighted the limits of prevalence studies.
- Published
- 2008
15. 093 OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY FOR INFECTIVE ENDOCARDITIS. SINGLE-CENTRE EXPERIENCE
- Author
-
Carlotto, A., Ferretto, R., Timillero, L., Rossi, L., Esposito, S., and Marranconi, F.
- Published
- 2009
- Full Text
- View/download PDF
16. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
- Author
-
Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Randi ML, Bertozzi I, Paoli C, Specchia G, Ricco A, Vannucchi AM, Rodeghiero F, Patrono C, and De Stefano V
- Subjects
- Adult, Aged, Aspirin pharmacokinetics, Cyclooxygenase 1 blood, Cyclooxygenase Inhibitors pharmacology, Double-Blind Method, Epoprostenol urine, Humans, Middle Aged, Platelet Aggregation Inhibitors pharmacokinetics, Thrombocythemia, Essential blood, Thrombocythemia, Essential urine, Aspirin administration & dosage, Cyclooxygenase Inhibitors administration & dosage, Platelet Aggregation Inhibitors administration & dosage
- Abstract
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet cyclooxygenase-1 (COX-1) inhibition. We performed a multicenter double-blind trial to investigate the efficacy of 3 aspirin regimens in optimizing platelet COX-1 inhibition while preserving COX-2-dependent vascular thromboresistance. Patients on chronic once-daily low-dose aspirin (n = 245) were randomized (1:1:1) to receive 100 mg of aspirin 1, 2, or 3 times daily for 2 weeks. Serum thromboxane B2 (sTXB2), a validated biomarker of platelet COX-1 activity, and urinary prostacyclin metabolite (PGIM) excretion were measured at randomization and after 2 weeks, as primary surrogate end points of efficacy and safety, respectively. Urinary TX metabolite (TXM) excretion, gastrointestinal tolerance, and ET-related symptoms were also investigated. Evaluable patients assigned to the twice-daily and thrice-daily regimens showed substantially reduced interindividual variability and lower median (interquartile range) values for sTXB2 (ng/mL) compared with the once-daily arm: 4 (2.1-6.7; n = 79), 2.5 (1.4-5.65, n = 79), and 19.3 (9.7-40; n = 85), respectively. Urinary PGIM was comparable in the 3 arms. Urinary TXM was reduced by 35% in both experimental arms. Patients in the thrice-daily arm reported a higher abdominal discomfort score. In conclusion, the currently recommended aspirin regimen of 75 to 100 once daily for cardiovascular prophylaxis appears to be largely inadequate in reducing platelet activation in the vast majority of patients with ET. The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosing interval to 12 hours, with no improvement with further reductions (EudraCT 2016-002885-30)., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.